Literature DB >> 34208452

ABHD4-Regulating RNA Panel: Novel Biomarkers in Acute Coronary Syndrome Diagnosis.

Sara H A Agwa1, Sherif Samir Elzahwy2, Mahmoud Shawky El Meteini3, Hesham Elghazaly4, Maha Saad5, Aya M Abd Elsamee6, Rania Shamekh7, Marwa Matboli8.   

Abstract

BACKGROUND: Acute coronary syndrome (ACS) is a major cause of death all over the world. STEMI represents a type of myocardial infarction with acute ST elevation. We aimed to assess the predictive power of potential RNA panel expression in acute coronary syndrome.
METHOD: We used in silico data analysis to retrieve RNAs related to glycerophospholipid metabolism dysregulation and specific to ACS that results in the selection of Alpha/Beta hydrolase fold domain4 (ABHD4) mRNA and its epigenetic regulators (Foxf1 adjacent noncoding developmental regulatory RNA (FENDRR) lncRNA, miRNA-221, and miRNA-197). We assessed the expression of the serum RNA panel in 68 patients with ACS, 21 patients with chest pain due to non-cardiac causes, and 21 healthy volunteers by quantitative real-time polymerase chain reaction.
RESULTS: The study data showed significant down regulation in the expression of the serum levels of FENDRR lncRNA and miRNA-221-3p by 120-fold and 22-fold in Unstable angina (UA) in comparison with healthy volunteers, and by 8.6-fold and 2-fold in ST segment elevation myocardial infarction (STEMI) patients versus UA; concomitant upregulation in the expression of ABHD4 mRNA and miRNA-197-5p by 444-fold and 10-fold in UA compared with healthy volunteers, and by 1.54-fold and 4.5-fold in STEMI versus unstable angina. Performance characteristics analysis showed that the ABHD4-regulating RNA panel were potential biomarkers for prediction of ACS. Moreover, there was a significant association between the 2 miRNAs and ABHD4 mRNA and the regulating FENDRR lncRNA.
CONCLUSION: Collectively, ABHD4 mRNA regulating RNA panel based on putative interactions seems to be novel non-invasive biomarkers that could detect ACS early and stratify severity of the condition that could improve health outcome.

Entities:  

Keywords:  RNA; acute coronary syndrome; bioinformatics; diagnosis; glycerophospholipid; serum; troponin

Year:  2021        PMID: 34208452     DOI: 10.3390/cells10061512

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  4 in total

1.  Targeting Circulating lncRNA ENST00000538705.1 Relieves Acute Coronary Syndrome via Modulating ALOX15.

Authors:  Hao Chen; Shiwei Huang; Fanlu Guan; Sisi Han; Fanhao Ye; Xun Li; Liyi You
Journal:  Dis Markers       Date:  2022-05-06       Impact factor: 3.464

2.  Association of fasting blood glucose to high-density lipoprotein cholesterol ratio with short-term outcomes in patients with acute coronary syndrome.

Authors:  Simin Deng; Zhaojun Wang; Yifeng Zhang; Ying Xin; Cheng Zeng; Xinqun Hu
Journal:  Lipids Health Dis       Date:  2022-01-30       Impact factor: 3.876

3.  Serum miR-497-5p serves as a diagnostic biomarker for acute coronary syndrome and predicts the occurrence of major adverse cardiovascular events after percutaneous coronary intervention.

Authors:  Tao Chen; Xueshan Zhang; Wei Qian; Ran Zhou; Mingyu Su; Yanfeng Ma
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 4.  Role of Different Types of miRNAs in Some Cardiovascular Diseases and Therapy-Based miRNA Strategies: A Mini Review.

Authors:  Safa S Fayez; Sami Mukhlif Mishlish; Hanan M Saied; Semaa A Shaban; Ahmed AbdulJabbar Suleiman; Firas Hassan; Ali Z Al-Saffar; Jameel R Al-Obaidi
Journal:  Biomed Res Int       Date:  2022-09-21       Impact factor: 3.246

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.